glp-1 vs peptides Diabetes Peptide Therapy Explained What is the Difference Between

GLP-1 S is semaglutide, a long-acting and selective GLP-1 receptor agonist

The researchers compared the one-year risk of heart failure hospitalization or death in new users of each GLP-1 drug to the risk of those outcomes in a placebo group of patients taking sitagliptin, a diabetes drug known to have no impact on HFpEF

What Are the Potential Side Effects of This Triple Agonist The most commonly reported adverse effects in clinical studies are gastrointestinal, consistent with the GLP-1 receptor agonist class

Healthcare Costs The widespread use of GLP-1 medications also has significant implications for healthcare costs